Skip Navigation


European Heart Journal Advance Access originally published online on January 9, 2009
European Heart Journal 2009 30(2):139-151; doi:10.1093/eurheartj/ehn538
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
30/2/139    most recent
ehn538v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cambronero, F.
Right arrow Articles by Lip, G. Y.H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cambronero, F.
Right arrow Articles by Lip, G. Y.H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org

Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis

Francisco Cambronero1, Francisco Marín1, Vanessa Roldán2, Diana Hernández-Romero1, Mariano Valdés1 and Gregory Y.H. Lip3,*

1 Department of Cardiology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain
2 Centro Regional de Hemodonación, University of Murcia, Spain
3 Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Dudley Road, Birmingham B18 7QH, UK

Received 24 May 2008; revised 6 November 2008; accepted 17 November 2008.

* Corresponding author. Tel: +44 121 5075080, Fax: +44 121 554 4083, Email: g.y.h.lip{at}bham.ac.uk

The study of biomarkers and their signalling pathways has allowed the development of new therapeutic strategies in a range of disorders. The aim of the present systematic review is to provide an overview of different biomarkers in patients with hypertrophic cardiomyopathy that could give some insight into the pathophysiologic mechanism(s) underlying the typical clinical and histological manifestations of the disease. Several pathophysiological models are presented and discussed, including studies that have investigated these biomarkers for diagnostic and prognostic reasons, in relation to disease progression and/or mortality.

Key Words: Hypertrophic cardiomyopathy • Biomarkers • Pathophysiology


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.